Prof Larry Egan

MB BCH BAO MRCPI MD

Contact Details

Professor
Dept of Pharmacology
Clinical Sciences Institute
NUI Galway
T: Ext. 5970
E: laurence.egan@nuigalway.ie
 
researcher
 

Biography

Prof. Egan graduated from UCG in 1990 (M.B., B.Ch., B.A.O.), and completed internship, house officer   and registrar training, based at University College Hospital Galway. He received Membership of RCPI in 1992, and Masters in Medical Science from UCG in 1994.  From 1994 to 1999, at the Mayo Clinic in Minnesota he completed further training in Internal Medicine, Clinical Pharmacology & Gastroenterology, receiving American Board certification in those 3 disciplines. NUI Galway conferred an MD in 1999.  Prof. Egan then undertook post-doctoral training from 2000 to 2002, in the Laboratory of Mucosal Immunology at the University of California, San Diego, before returning to the Mayo Clinic to take up a consultancy in Gastroenterology, with joint appointment in the Department of Molecular Pharmacology and Experimental Therapeutics. His research focuses on molecular characterization of signaling pathways involved in intestinal epithelial cell stress, death and malignant transformation, and optimization of personalized approaches to biological therapy in inflammatory bowel diseases. In 2005, Prof. Egan joined NUI Galway and the Health Service Executive Western Region as Professor of Clinical Pharmacology/Consultant Clinical Pharmacologist and Head of the Department of Pharmacology & Therapeutics, a position he took up in August 2005. Prof. Egan has served as Interim Director of the HRB Clinical Research facility Galway, as Vice-Dean of Research at the College of Medicine Nursing and Health Sciences at NUI Galway, and as Head of the discipline of Pharmacology and Therapeutics. He is a past-President of the Irish Society of Gastroenterology. He was associate editor at Gut, and has been editor-in-chief of the Journal of Crohn’s and Colitis since 2014.



Peer Reviewed Journals

  Year Publication
'Thromboxane A2 and prostacyclin receptors exert opposing effects on the severity of experimental murine colitis'
Egan, L. J., Smith, J. R., Truong, F., Kirstein, S., Sugimoto, Y., Narumiya, S., Varki, N. M., Insel, P. A., Kagnoff, M. F. & Eckmann, L. 'Thromboxane A2 and prostacyclin receptors exert opposing effects on the severity of experimental murine colitis'. [Details]
(2020) 'Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction'
Gibson, DJ;Doherty, J;McNally, M;Campion, J;Keegan, D;Keogh, A;Kennedy, U;Byrne, K;Egan, LJ;McKiernan, S;MacCarthy, F;Sengupta, S;Sheridan, J;Mulcahy, HE;Cullen, G;Slattery, E;Kevans, D;Doherty, GA (2020) 'Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction'. Frontline Gastroenterology, 11 :441-447 [DOI] [Details]
(2020) 'The pseudo-caspase FLIP(L) regulates cell fate following p53 activation'
Lees, A,McIntyre, AJ,Crawford, NT,Falcone, F,McCann, C,Holohan, C,Quinn, GP,Roberts, JZ,Sessler, T,Gallagher, PF,Gregg, GMA,McAllister, K,McLaughlin, KM,Allen, WL,Egan, LJ,Ryan, AE,Labonte-Wilson, MJ,Dunne, PD,Wappett, M,Coyle, VM,Johnston, PG,Kerr, EM,Longley, DB,McDade, SS (2020) 'The pseudo-caspase FLIP(L) regulates cell fate following p53 activation'. Proceedings Of The National Academy Of Sciences Of The United States Of America, 117 :17808-17819 [DOI] [Details]
(2020) 'The pseudo-caspase FLIP(L) regulates cell fate following p53 activation'
Lees A;McIntyre AJ;Crawford NT;Falcone F;McCann C;Holohan C;Quinn GP;Roberts JZ;Sessler T;Gallagher PF;Gregg GMA;McAllister K;McLaughlin KM;Allen WL;Egan LJ;Ryan AE;Labonte-Wilson MJ;Dunne PD;Wappett M;Coyle VM;Johnston PG;Kerr EM;Longley DB;McDade SS; (2020) 'The pseudo-caspase FLIP(L) regulates cell fate following p53 activation'. Proceedings Of The National Academy Of Sciences Of The United States Of America, [DOI] [Details]
(2020) 'Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction'
Gibson, DJ,Doherty, J,McNally, M,Campion, J,Keegan, D,Keogh, A,Kennedy, U,Byrne, K,Egan, LJ,McKiernan, S,MacCarthy, F,Sengupta, S,Sheridan, J,Mulcahy, HE,Cullen, G,Slattery, E,Kevans, D,Doherty, GA (2020) 'Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction'. Frontline Gastroenterology, 11 :441-447 [DOI] [Details]
(2019) 'Inhibition of anti-viral responses in intestinal epithelial cells by epigenetic modifying drugs is mediated by a reduction in viral pattern recognition receptor expression and activity'
Hennessy, C; O'Connell, S; Egan, LJ; McKernan, DP. (2019) 'Inhibition of anti-viral responses in intestinal epithelial cells by epigenetic modifying drugs is mediated by a reduction in viral pattern recognition receptor expression and activity'. Immunopharmacology And Immunotoxicology, 41 (5):527-537 [DOI] [Details]
(2018) 'Stromal Cell PD-L1 Inhibits CD8(+) T-cell Antitumor Immune Responses and Promotes Colon Cancer'
O'Malley, G,Treacy, O,Lynch, K,Naicker, SD,Leonard, NA,Lohan, P,Dunne, PD,Ritter, T,Egan, LJ,Ryan, AE (2018) 'Stromal Cell PD-L1 Inhibits CD8(+) T-cell Antitumor Immune Responses and Promotes Colon Cancer'. Cancer Immunology Research, 6 :1426-1441 [DOI] [ARAN Link] [Details]
(2017) 'Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis'
Barnicle, A,Seoighe, C,Greally, JM,Golden, A,Egan, LJ (2017) 'Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis'. Epigenetics, 12 :591-606 [DOI] [Details]
(2016) 'Differential DNA methylation patterns of homeobox genes in proximal and distal colon epithelial cells'
Barnicle, A,Seoighe, C,Golden, A,Greally, JM,Egan, LJ (2016) 'Differential DNA methylation patterns of homeobox genes in proximal and distal colon epithelial cells'. Physiological Genomics, 48 :257-273 [DOI] [Details]
(2016) 'Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?'
O'Malley G;Heijltjes M;Houston AM;Rani S;Ritter T;Egan LJ;Ryan AE; (2016) 'Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?'. Oncotarget, 7 (37):60752-60774 [DOI] [Details]
(2016) 'Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in Crohn's Disease'
Slevin, SM,Dennedy, MC,Connaughton, EP,Ribeiro, A,Ceredig, R,Griffin, MD,Egan, LJ (2016) 'Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in Crohn's Disease'. Inflammatory Bowel Diseases, 22 :2863-2878 [DOI] [Details]
(2016) 'Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?'
O'Malley, G; Heijltjes, M; Houston, AM; Rani, S; Ritter, T; Egan, LJ; Ryan, AE (2016) 'Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?'. Oncotarget, 7 (37):60752-60773 [DOI] [Details]
(2016) 'Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in Crohn's Disease'
Slevin SM, Dennedy MC, Connaughton EP, Ribeiro A, Ceredig Rh, Griffin MD, Egan LJ. (2016) 'Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in Crohn's Disease'. Inflammatory Bowel Diseases, 22 (12):2663-2878 [Details]
(2015) 'Effect of Genetic Deletion or Pharmacological Antagonism of Tumor Necrosis Factor Alpha on Colitis-associated Carcinogenesis in Mice'
Craven, B,Zaric, V,Martin, A,Mureau, C,Egan, LJ (2015) 'Effect of Genetic Deletion or Pharmacological Antagonism of Tumor Necrosis Factor Alpha on Colitis-associated Carcinogenesis in Mice'. Inflammatory Bowel Diseases, 21 :485-495 [DOI] [Details]
(2015) 'The intestinal epithelial cell cycle: uncovering its 'cryptic' nature'
McKernan DP, Egan LJ. (2015) 'The intestinal epithelial cell cycle: uncovering its 'cryptic' nature'. Current Opinion In Gastroenterology, 31 (2):124-129 [DOI] [Details]
(2015) 'Targeting colon cancer cell NF-kappa B promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis'
Ryan, AE,Colleran, A,O'Gorman, A,O'Flynn, L,Pindjacova, J,Lohan, P,O'Malley, G,Nosov, M,Mureau, C,Egan, LJ (2015) 'Targeting colon cancer cell NF-kappa B promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis'. Oncogene, 34 :1563-1574 [DOI] [Details]
(2015) 'New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-alpha Monoclonal Antibodies in Inflammatory Bowel Disease'
Slevin, SM,Egan, LJ (2015) 'New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-alpha Monoclonal Antibodies in Inflammatory Bowel Disease'. Inflammatory Bowel Diseases, 21 :2909-2920 [DOI] [Details]
(2014) 'Targeting colon cancer cell NF-&;IcircºB promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis'
Ryan AE, Colleran A, O'Gorman A, O'Flynn L, Pindjacova J, Lohan P, O'Malley G, Nosov M, Mureau C, Egan LJ (2014) 'Targeting colon cancer cell NF-&;IcircºB promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis'. Oncogene, 0 [DOI] [Details]
(2013) 'Gastrointestinal radiation injury: Prevention and treatment'
Shadad, AK,Sullivan, FJ,Martin, JD,Egan, LJ (2013) 'Gastrointestinal radiation injury: Prevention and treatment'. World Journal Of Gastroenterology, 19 :199-208 [DOI] [Details]
(2013) 'Smoking and Crohn's disease: Active modification of an independent risk factor (Education alone is not enough)'
Kennelly, RP;Subramaniam, T;Egan, LJ;Joyce, MR (2013) 'Smoking and Crohn's disease: Active modification of an independent risk factor (Education alone is not enough)'. Journal Of Crohns & Colitis, 7 :631-635 [DOI] [Details]
(2013) 'Gene-set analysis is severely biased when applied to genome-wide methylation data'
Geeleher, P;Hartnett, L;Egan, LJ;Golden, A;Ali, RAR;Seoighe, C (2013) 'Gene-set analysis is severely biased when applied to genome-wide methylation data'. Bioinformatics, 29 :1851-1857 [DOI] [Details]
(2013) 'The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action'
Kerr, DM;Harhen, B;Okine, BN;Egan, LJ;Finn, DP;Roche, M (2013) 'The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action'. British Journal Of Pharmacology, 169 :808-819 [DOI] [Details]
(2013) 'Gastrointestinal radiation injury: prevention and treatment'
Shadad AK, Sullivan FJ, Martin JD, Egan LJ. (2013) 'Gastrointestinal radiation injury: prevention and treatment'. American Journal Of Gastroenterology, 19 (2):199-208 [Details]
(2013) 'Pharmacological inhibition of monoacylglycerol lipase attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action'
Kerr DM, Harhen B, Egan LJ, Finn DP, Roche M (2013) 'Pharmacological inhibition of monoacylglycerol lipase attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action'. British Journal Of Pharmacology, 169 (4):808-819 [DOI] [ARAN Link] [Details]
(2013) 'The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action'
Kerr, DM,Harhen, B,Okine, BN,Egan, LJ,Finn, DP,Roche, M (2013) 'The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action'. British Journal Of Pharmacology, 169 :808-819 [DOI] [Details]
(2013) 'Gastrointestinal radiation injury: Symptoms, risk factors and mechanisms'
Shadad, AK,Sullivan, FJ,Martin, JD,Egan, LJ (2013) 'Gastrointestinal radiation injury: Symptoms, risk factors and mechanisms'. World Journal Of Gastroenterology, 19 :185-198 [DOI] [Details]
(2013) 'Gene-set analysis is severely biased when applied to genome-wide methylation data'
Geeleher, P,Hartnett, L,Egan, LJ,Golden, A,Ali, RAR,Seoighe, C (2013) 'Gene-set analysis is severely biased when applied to genome-wide methylation data'. Bioinformatics, 29 :1851-1857 [DOI] [Details]
(2013) 'Smoking and Crohn's disease: Active modification of an independent risk factor (Education alone is not enough)'
Kennelly, RP,Subramaniam, T,Egan, LJ,Joyce, MR (2013) 'Smoking and Crohn's disease: Active modification of an independent risk factor (Education alone is not enough)'. Journal Of Crohns & Colitis, 7 :631-635 [DOI] [Details]
(2013) 'Suppression of radiation-induced DNA double-strand break repair by MyD88 is accompanied by apoptosis and crypt loss in mouse colon'
Lai, XY,Egan, LJ (2013) 'Suppression of radiation-induced DNA double-strand break repair by MyD88 is accompanied by apoptosis and crypt loss in mouse colon'. Oncogenesis, 2 [DOI] [Details]
(2012) 'Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the rat hypothalamus following an immunological stressor'
Kerr, DM;Burke, NN;Ford, GK;Connor, TJ;Harhen, B;Egan, LJ;Finn, DP;Roche, M (2012) 'Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the rat hypothalamus following an immunological stressor'. Neuroscience, 204 :53-63 [DOI] [Details]
(2011) 'Autophagosomal IkBa degradation plays a role in the long term control of tumor necrosis factor-a-induced NF-kB activation'
Colleran A, O'Gorman A, Ryan A, Mureau C, Liptrot C, Dockery P, Fearnhead H, Egan L. (2011) 'Autophagosomal IkBa degradation plays a role in the long term control of tumor necrosis factor-a-induced NF-kB activation'. Journal of Biological Chemistry, 286 :22886-22893 [DOI] [Details]
(2011) 'Autophagosomal IkappaB alpha degradation plays a role in the long term control of tumor necrosis factor-alpha-induced nuclear factor-kappaB (NF-kappaB) activity'
Colleran A, Ryan A, O'Gorman A, Mureau C, Liptrot C, Dockery P, Fearnhead H, Egan LJ (2011) 'Autophagosomal IkappaB alpha degradation plays a role in the long term control of tumor necrosis factor-alpha-induced nuclear factor-kappaB (NF-kappaB) activity'. Journal Of Biological Chemistry, 286 (26):22886-22893 [DOI] [Details]
(2011) 'Mechanisms of Drug Toxicity or Intolerance'
Egan, LJ (2011) 'Mechanisms of Drug Toxicity or Intolerance'. Journal Of Digestive Diseases, 29 :172-176 [DOI] [Details]
(2011) 'Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease'
Ali, RAR;Dooley, C;Comber, H;Newell, J;Egan, LJ (2011) 'Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease'. Clinical Gastroenterology And Hepatology, 9 :584-104 [DOI] [Details]
(2011) 'Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease'
Ali, RAR,Dooley, C,Comber, H,Newell, J,Egan, LJ (2011) 'Clinical Features, Treatment, and Survival of Patients With Colorectal Cancer With or Without Inflammatory Bowel Disease'. Clinical Gastroenterology And Hepatology, 9 :584-104 [DOI] [Details]
(2011) 'Autophagosomal I kappa B alpha Degradation Plays a Role in the Long Term Control of Tumor Necrosis Factor-alpha-induced Nuclear Factor-kappa B (NF-kappa B) Activity'
Colleran, A,Ryan, A,O'Gorman, A,Mureau, C,Liptrot, C,Dockery, P,Fearnhead, H,Egan, LJ (2011) 'Autophagosomal I kappa B alpha Degradation Plays a Role in the Long Term Control of Tumor Necrosis Factor-alpha-induced Nuclear Factor-kappa B (NF-kappa B) Activity'. Journal Of Biological Chemistry, 286 :22886-22893 [DOI] [Details]
(2011) 'Mechanisms of Drug Toxicity or Intolerance'
Egan, LJ (2011) 'Mechanisms of Drug Toxicity or Intolerance'. Digestive Diseases, 29 :172-176 [DOI] [Details]
(2010) 'Upregulation of DNA Methyltransferase-Mediated Gene Silencing, Anchorage-Independent Growth, and Migration of Colon Cancer Cells by Interleukin-6'
Foran, E;Garrity-Park, MM;Mureau, C;Newell, J;Smyrk, TC;Limburg, PJ;Egan, LJ (2010) 'Upregulation of DNA Methyltransferase-Mediated Gene Silencing, Anchorage-Independent Growth, and Migration of Colon Cancer Cells by Interleukin-6'. Molecular Cancer Research, 8 :471-481 [DOI] [Details]
(2010) 'Regulation of NF-kappa B responses by epigenetic suppression of I kappa B alpha expression in HCT116 intestinal epithelial cells'
O'Gorman, A;Colleran, A;Ryan, A;Mann, J;Egan, LJ (2010) 'Regulation of NF-kappa B responses by epigenetic suppression of I kappa B alpha expression in HCT116 intestinal epithelial cells'. American Journal Of Physiology: Gastrointestinal And Liver Physiology, 299 :96-105 [DOI] [Details]
(2010) 'The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival'
Rahman MK, Midtling EH, Svingen PA, Xiong Y, Bell MP, Tung J, Smyrk T, Egan LJ, Faubion WA Jr. (2010) 'The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival'. J. Immunol, 184 (12):7247-7256 [Details]
(2010) 'Upregulation of DNA methyltransferase-mediated gene silencing, anchorage independent growth and migration of colon cancer cells by interleukin-6'
Foran E, Garrity-Park M., Mureau C, Newell J, Smyrk TC, Limburg PJ, Egan LJ. (2010) 'Upregulation of DNA methyltransferase-mediated gene silencing, anchorage independent growth and migration of colon cancer cells by interleukin-6'. Molecular Cancer Research, 8 (4):471-481 [Details]
(2010) 'Regulation of NF-kappa B responses by epigenetic suppression of I kappa B alpha expression in HCT116 intestinal epithelial cells'
O'Gorman, A,Colleran, A,Ryan, A,Mann, J,Egan, LJ (2010) 'Regulation of NF-kappa B responses by epigenetic suppression of I kappa B alpha expression in HCT116 intestinal epithelial cells'. American Journal Of Physiology-Gastrointestinal And Liver Physiology, 299 :96-105 [DOI] [Details]
(2010) 'Upregulation of DNA Methyltransferase-Mediated Gene Silencing, Anchorage-Independent Growth, and Migration of Colon Cancer Cells by Interleukin-6'
Foran, E,Garrity-Park, MM,Mureau, C,Newell, J,Smyrk, TC,Limburg, PJ,Egan, LJ (2010) 'Upregulation of DNA Methyltransferase-Mediated Gene Silencing, Anchorage-Independent Growth, and Migration of Colon Cancer Cells by Interleukin-6'. Molecular Cancer Research, 8 :471-481 [DOI] [Details]
(2009) 'Is there a role for NF?B in TRAIL resistance. Ann N.Y'
Plantivaux A, Szegezdi E, Samali A, Egan L. (2009) 'Is there a role for NF?B in TRAIL resistance. Ann N.Y'. Academy Sci, 1171 :38-49 [Details]
(2009) 'Inhibition of NF-?B in colon cancer significantly decreases tumour burden and increases survival time in a mouse model of peritoneal metastasis'
Ryan A, Colleran A, O'Gorman A, Foran E, Egan LJ. (2009) 'Inhibition of NF-?B in colon cancer significantly decreases tumour burden and increases survival time in a mouse model of peritoneal metastasis'. Poster Presentation, DDW, Chicago, [Details]
(2008) 'Inhibition of NF-?B in colon cancer cells significantly decreases tumour burden and increases host survival time in a mouse model of peritoneal metastasis'
Ryan A, Colleran A, O'Gorman A, Foran E, Egan LJ. (2008) 'Inhibition of NF-?B in colon cancer cells significantly decreases tumour burden and increases host survival time in a mouse model of peritoneal metastasis'. Presented at Keystone Symposia, Banff, CA, [Details]
(2008) 'Microenvironment to nucleus signaling: Interleukin-6 decreases tumor suppressor gene expression in HCT116 cells through DNMT1-mediated epigenetic silencing'
Foran E, Egan LJ. (2008) 'Microenvironment to nucleus signaling: Interleukin-6 decreases tumor suppressor gene expression in HCT116 cells through DNMT1-mediated epigenetic silencing'. Presented at Keystone Symposia, Banff, CA, [Details]
(2008) 'Risk factors for opportunistic infections in patients with inflammatory bowel disease'
Toruner, M,Loftus, EV,Harmsen, WS,Zinsmeister, AR,Orenstein, R,Sandborn, WJ,Colombel, JF,Egan, LJ (2008) 'Risk factors for opportunistic infections in patients with inflammatory bowel disease'. Gastroenterology, 134 :929-936 [DOI] [Details]
(2008) 'Inflammatory Bowel Diseases'
Egan LJ. Maaser C. (2008) 'Inflammatory Bowel Diseases'. Pharmacology and Therapeutics, Principles to Practice, 33 :487-503 [Details]
(2008) 'Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial'
Solem, CA,Loftus, EV,Fletcher, JG,Baron, TH,Gostout, CJ,Petersen, BT,Tremaine, WJ,Egan, LJ,Faubion, WA,Schroeder, KW,Pardi, DS,Hanson, KA,Jewell, DA,Barlow, JM,Fidler, JL,Huprich, JE,Johnson, CD,Harmsen, WS,Zinsmeister, AR,Sandborn, WJ (2008) 'Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial'. Gastrointest Endosc, 68 :255-266 [DOI] [Details]
(2008) 'Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial'
Solem, CA;Loftus, EV;Fletcher, JG;Baron, TH;Gostout, CJ;Petersen, BT;Tremaine, WJ;Egan, LJ;Faubion, WA;Schroeder, KW;Pardi, DS;Hanson, KA;Jewell, DA;Barlow, JM;Fidler, JL;Huprich, JE;Johnson, CD;Harmsen, WS;Zinsmeister, AR;Sandborn, WJ (2008) 'Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial'. Gastrointestinal Endoscopy, 68 :255-266 [DOI] [Details]
(2008) 'Inflammation and Immunomodulation'
Egan LJ. (2008) 'Inflammation and Immunomodulation'. Pharmacology and Therapeutics, Principles to Practice, 11 :157-172 [Details]
(2008) 'Longterm suppression of I?Ba by inflammatory cytokines:'
Colleran A, Ryan A, Egan LJ. (2008) 'Longterm suppression of I?Ba by inflammatory cytokines:'. Molecular Mechanisms. Presented at Keystone Symposia, Banff, CA, [Details]
(2008) 'Risk factors for opportunistic infections in patients with inflammatory bowel disease'
Toruner, M;Loftus, EV;Harmsen, WS;Zinsmeister, AR;Orenstein, R;Sandborn, WJ;Colombel, JF;Egan, LJ (2008) 'Risk factors for opportunistic infections in patients with inflammatory bowel disease'. Gastroenterology, 134 :929-936 [DOI] [Details]
(2008) 'I?Ba as a target for epigenetic silencing in colon cancer'
O'Gorman A, Ryan A, Foran E, Mureau C, Egan LJ. (2008) 'I?Ba as a target for epigenetic silencing in colon cancer'. Presented at Keystone Symposia, Banff CA, [Details]
(2007) 'Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2'
Kang-Decker N, Cao S, Chatteriee S, Yao J, Egan LJ, Semela D, Mukhopadhyay D, Shah V. (2007) 'Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2'. Journal of Cellular Science, 1 (120(Pt 3)):492-501 [Details]
(2007) 'Gastroesophageal reflux disease in pregnancy'
Ali, RAR,Egan, LJ (2007) 'Gastroesophageal reflux disease in pregnancy'. Best Practice & Research In Clinical Gastroenterology, 21 :793-806 [DOI] [Details]
(2007) 'Allopurinol and 6MP: Steering through the therapeutic obstacle course'
Egan LJ. (2007) 'Allopurinol and 6MP: Steering through the therapeutic obstacle course'. Inflammatory Bowel Disease, 13 (10):1312-1313 [DOI] [Details]
(2007) 'A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain'
Egan LJ. (2007) 'A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain'. Clinical gastroenterology and Hepatology, 5 (2):170-171 [Details]
(2007) 'Gastroesophageal reflux disease in pregnancy'
Ali, RAR;Egan, LJ (2007) 'Gastroesophageal reflux disease in pregnancy'. Best Practice And Research Clinical Gastroenterology, 21 :793-806 [DOI] [Details]
(2006) 'The AmpliChip CYP450 test: Principles, challenges, and future clinical utility in digestive disease'
Juran, BD,Egan, LJ,Lazaridis, KN (2006) 'The AmpliChip CYP450 test: Principles, challenges, and future clinical utility in digestive disease'. Clinical Gastroenterology And Hepatology, 4 :822-830 [DOI] [Details]
(2006) 'Antianoikis effect of nuclear factor-kappa B through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1'
Toruner, M;Fernandez-Zapico, M;Sha, JJ;Pham, L;Urrutia, R;Egan, LJ (2006) 'Antianoikis effect of nuclear factor-kappa B through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1'. Journal Of Biological Chemistry, 281 :8686-8696 [DOI] [Details]
(2006) 'Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice'
Chopra A, Pardi DS, Loftus EV Jr, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ. (2006) 'Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice'. Inflammatory Bowel Disease, 12 (1):29-32 [Details]
(2006) 'Pharmacogenomics in inflammatory bowel disease'
Egan, LJ,Derijks, LJJ,Hommes, DW (2006) 'Pharmacogenomics in inflammatory bowel disease'. Clinical Gastroenterology And Hepatology, 4 :21-28 [DOI] [Details]
(2006) 'Pharmacogenomics in inflammatory bowel disease'
Egan, LJ;Derijks, LJJ;Hommes, DW (2006) 'Pharmacogenomics in inflammatory bowel disease'. Clinical Gastroenterology And Hepatology, 4 :21-28 [DOI] [Details]
(2006) 'The AmpliChip CYP450 test: Principles, challenges, and future clinical utility in digestive disease'
Juran, BD;Egan, LJ;Lazaridis, KN (2006) 'The AmpliChip CYP450 test: Principles, challenges, and future clinical utility in digestive disease'. Clinical Gastroenterology And Hepatology, 4 :822-830 [DOI] [Details]
(2006) 'NF-kappa B signaling - Pros and cons of altering NF-kappa B as a therapeutic approach'
Egan, LJ,Toruner, M,Domschke, WW,Kagnoff, MF,Kucharzik, TF,Mayer, LF,Targan Sr (2006) 'NF-kappa B signaling - Pros and cons of altering NF-kappa B as a therapeutic approach'. Annals Of The New York Academy Of Sciences, 1072 :114-122 [DOI] [Details]
(2006) 'Antianoikis effect of nuclear factor-kappa B through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1'
Toruner, M,Fernandez-Zapico, M,Sha, JJ,Pham, L,Urrutia, R,Egan, LJ (2006) 'Antianoikis effect of nuclear factor-kappa B through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1'. Journal Of Biological Chemistry, 281 :8686-8696 [DOI] [Details]
(2005) 'Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines'
Thomas, C., Myhre, G. M., Tschumper, R., Sreekumar, R., Jelinek, D., McKean, D. J., Sandborn, W. J., Lipsky, J. J. & Egan, L. J. (2005) 'Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines'. Journal of Pharmacology and Experimental Therapeutics, 312 (2):537-545 [Details]
(2005) 'Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease'
Toruner M, Harewood GC, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Faubion WA, Schroeder KW, Egan LJ (2005) 'Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease'. Inflammatory Bowel Diseases, 11 (5):428-434 [Details]
(2005) 'Positioning novel biologic, probiotic, and apheresis therapies for Chron's disease and ulcerative colitis'
Egan, L. J. and Sandborn, W. J. (2005) 'Positioning novel biologic, probiotic, and apheresis therapies for Chron's disease and ulcerative colitis'. Current Gastroenterology Reports, 7 (6):485-491 [Details]
(2005) 'Acute pancreatitis in Crohn's disease: clinical features and outcomes'
Moolsintong P, Loftus EV Jr, Chari ST, Egan LJ, Tremaine WJ, Sandborn WJ (2005) 'Acute pancreatitis in Crohn's disease: clinical features and outcomes'. Inflammatory Bowel Diseases, 11 (12):1080-1084 [Details]
(2004) 'Drug interactions in gastroenterology: mechanisms, consequences and how to avoid'
Egan, L. J. (2004) 'Drug interactions in gastroenterology: mechanisms, consequences and how to avoid'. Clinical Gastroenterology and Hepatology, 2 (9):725-730 [Details]
(2004) 'IKK -dependent NF- B activation provides radioprotection to the intestinal epithelium'
Egan, L. J., Eckmann, L., Greten, F., Chae, S., Li, Z-W., Myhre, G. M., Robine, S., Karin, M. & Kagnoff, M. F. (2004) 'IKK -dependent NF- B activation provides radioprotection to the intestinal epithelium'. Proceedings of the National Academy of Sciences USA, 101 :2452-2457 [Details]
(2004) 'Metalloprotease disintegrin-mediated ectodomain shedding of EGFR ligands promotes intestinal epithelial restitution'
Myhre, G. M., Toruner, M., Abraham, S. & Egan, L. J. (2004) 'Metalloprotease disintegrin-mediated ectodomain shedding of EGFR ligands promotes intestinal epithelial restitution'. American Journal of Physiology: Gastrointestinal and Liver Physiology, 10 [Details]
(2004) 'The safety profile of Infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients'
Colombel, J-F., Loftus, E. V. Jr, Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R. & Sandborn, W. J. (2004) 'The safety profile of Infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients'. Gastroenterology, 126 (1):19-31 [Details]
(2004) 'Expression of EBI3 and related molecules by human intestinal epithelium'
Maaser, C., Egan, L. J., Birkenbach, M. P., Eckmann, L. & Kagnoff, M. F. (2004) 'Expression of EBI3 and related molecules by human intestinal epithelium'. Immunology, 112 (Issue no 3):437-445 [Details]
(2004) 'Cyclosporine, Tacrolimus and Mycophenolate Mofetil in the treatment of inflammatory bowel disease'
Loftus, C. G., Egan, L. J. & Sandborn, W. J. (2004) 'Cyclosporine, Tacrolimus and Mycophenolate Mofetil in the treatment of inflammatory bowel disease'. Gastroenterology Clinics of North America, 33 (2):141-169 [Details]
(2004) 'IKK links inflammation and tumorigenesis in a mouse model of colitis-associated cancer'
Greten, F. R., Eckmann, L., Greten, T. F., Park, J-M., Li, Z-W., Egan, L. J., Kagnoff, M. F. & Karin, M. (2004) 'IKK links inflammation and tumorigenesis in a mouse model of colitis-associated cancer'. Cell, 118 :285-296 [Details]
(2004) 'Advances in the treatment of Crohn's disease'
Egan, L. J. & Sandborn, W. M. (2004) 'Advances in the treatment of Crohn's disease'. Gastroenterology, 126 (6):1574-1581 [Details]
(2003) 'CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-esophageal reflux disease: variant alleles predict gastric acid suppression, but not esophageal acid exposure or reflux symptoms'
Egan, L. J., Myhre, G. M., Mays, D. C., Dierkhising, R. A., Kammer, P. P. & Murray, J. A. (2003) 'CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-esophageal reflux disease: variant alleles predict gastric acid suppression, but not esophageal acid exposure or reflux symptoms'. Alimentary Pharmacology & Therapeutics, 172 (12):1521-1528 [Details]
(2003) 'The two faces of IKK and NF- B inhibition, prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion'
Chen, L-W., Egan, L. J., Li, Z-W., Kagnoff, M. F. & Karin, M. (2003) 'The two faces of IKK and NF- B inhibition, prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion'. Nature Medicine, 9 (5):575-581 [Details]
(2003) 'Nuclear factor B activation promotes restitution of wounded intestinal epithelial monolayers'
Egan, L. J., De Lecea, A., Lehrman, E. D., Myhre, G. M., Eckmann, L. & Kagnoff, M. F. (2003) 'Nuclear factor B activation promotes restitution of wounded intestinal epithelial monolayers'. American Journal of Physiology: Cell Physiology, 285 (5):C1028-C1035 [Details]
(2002) 'Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF- B and MAP kinase pathways and the upregulated expression of interleukin-8'
Berin, M. C., Darfeuille-Michaud, A., Egan, L. J., Miyamoto, Y. & Kagnoff, M. F. (2002) 'Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF- B and MAP kinase pathways and the upregulated expression of interleukin-8'. Cellular Microbiology, 4 :635-647 [Details]
(2000) 'New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors'
Egan, L. J. & Murray, J. A. (2000) 'New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors'. Digestive Diseases, 18 :58-63 [Details]
(2000) 'Endoscopic removal of an embedded biliary Wallstent by piecemeal extraction'
Egan, L. J. & Baron, T. H. (2000) 'Endoscopic removal of an embedded biliary Wallstent by piecemeal extraction'. Endoscopy, 32 :492-494 [Details]
(2000) 'Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate in treatment resistant inflammatory bowel diseas'
Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (2000) 'Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate in treatment resistant inflammatory bowel diseas'. Inflammatory Bowel Diseases, 6 :286-289 [Details]
(1999) 'Inhibition of interleukin-1-stimulated NF- B RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity'
Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1999) 'Inhibition of interleukin-1-stimulated NF- B RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity'. Journal of Biological Chemistry, 274 :26448-26453 [Details]
(1999) 'A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis'
Egan, L. J., Sandborn, W. J., Tremaine, W. J., Leighton, J. A., Mays, D. C., Pike, M. G., Zinsmeister, A. R. & Lipsky, J. J. (1999) 'A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis'. Alimentary Pharmacology & Therapeutics, 13 :1597-1604 [Details]
(1999) 'The intestinal and systemic pharmacokinetics of methotrexate in inflammatory bowel disease patients'
Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1999) 'The intestinal and systemic pharmacokinetics of methotrexate in inflammatory bowel disease patients'. Clinical Pharmacology & Therapeutics, 65 :29-39 [Details]
(1999) 'Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate'
Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1999) 'Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate'. Inflammatory Bowel Diseases, 5 :167-173 [Details]
(1998) 'Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine'
Egan, L. J, Sandborn, W. J. & Tremaine, W. J. (1998) 'Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine'. American Journal of Gastroenterology, 93 :442-448 [Details]
(1998) 'Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision'
Egan, L. J., Sandborn, W. J., Mays, D. C., Tremaine, W. J. & Lipsky, J. J. (1998) 'Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision'. Alimentary Pharmacology and Therapeutics, 12 :679-684 [Details]
(1998) 'Herpetic whitlow of the toe: an unusual manifestation of infection with Herpes Simplex virus type 2'
Egan, L. J., Bylander, J. M., Agerter, D. C. & Edson, R. S. (1998) 'Herpetic whitlow of the toe: an unusual manifestation of infection with Herpes Simplex virus type 2'. Clinical Infectious Diseases, 26 :196-197 [Details]
(1996) 'Methotrexate for inflammatory bowel disease: pharmacology and preliminary results'
Egan L. J. & Sandborn W. J. (1996) 'Methotrexate for inflammatory bowel disease: pharmacology and preliminary results'. Mayo Clinic Proceedings, 71 (1):69-80 [Details]
(1995) 'CELIAC-ASSOCIATED LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE OF 30 CASES IN THE COMBINATION CHEMOTHERAPY ERA'
EGAN, LJ;WALSH, SV;STEVENS, FM;CONNOLLY, CE;EGAN, EL;MCCARTHY, CF (1995) 'CELIAC-ASSOCIATED LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE OF 30 CASES IN THE COMBINATION CHEMOTHERAPY ERA'. Journal Of Clinical Gastroenterology, 21 :123-129 [Details]
(1995) 'ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA IN THE WEST OF IRELAND - LOW-FREQUENCY OF EPSTEIN-BARR-VIRUS IN THESE TUMORS'
WALSH, SV,EGAN, LJ,CONNOLLY, CE,STEVENS, FM,EGAN, EL,MCCARTHY, CF (1995) 'ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA IN THE WEST OF IRELAND - LOW-FREQUENCY OF EPSTEIN-BARR-VIRUS IN THESE TUMORS'. Modern Pathology, 8 :753-757 [Details]
(1995) 'ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA IN THE WEST OF IRELAND - LOW-FREQUENCY OF EPSTEIN-BARR-VIRUS IN THESE TUMORS'
WALSH, SV;EGAN, LJ;CONNOLLY, CE;STEVENS, FM;EGAN, EL;MCCARTHY, CF (1995) 'ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA IN THE WEST OF IRELAND - LOW-FREQUENCY OF EPSTEIN-BARR-VIRUS IN THESE TUMORS'. Modern Pathology, 8 :753-757 [Details]
(1995) 'CELIAC-ASSOCIATED LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE OF 30 CASES IN THE COMBINATION CHEMOTHERAPY ERA'
EGAN, LJ,WALSH, SV,STEVENS, FM,CONNOLLY, CE,EGAN, EL,MCCARTHY, CF (1995) 'CELIAC-ASSOCIATED LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE OF 30 CASES IN THE COMBINATION CHEMOTHERAPY ERA'. Journal Of Clinical Gastroenterology, 21 :123-129 [Details]
(1995) 'Enteropathy associated T cell lymphoma; Low frequency of Epstein Barr virus in these tumors'
Walsh, S. V., Egan, L. J., Connolly, C. E., Egan, E. L., Stevens, F. M. & McCarthy, C. F. (1995) 'Enteropathy associated T cell lymphoma; Low frequency of Epstein Barr virus in these tumors'. Modern Pathology, 8 (7) [Details]
(1995) 'Celiac associated lymphoma a single institution experience of 30 cases in the combination chemotherapy era'
Egan, L. J., Walsh, S. V., Stevens, F. M., Connolly, C. E., Egan, E. L. & McCarthy, C. F. (1995) 'Celiac associated lymphoma a single institution experience of 30 cases in the combination chemotherapy era'. Journal of Clinical Gastroenterology, 21 (2):123-129 [Details]
(1994) 'HEREDITARY-DEFICIENCY OF THE 7TH COMPONENT OF COMPLEMENT AND RECURRENT MENINGOCOCCAL INFECTION - INVESTIGATIONS OF AN IRISH FAMILY USING A NOVEL HEMOLYTIC SCREENING ASSAY FOR COMPLEMENT ACTIVITY AND C7 M/N ALLOTYPING'
EGAN, LJ;ORREN, A;DOHERTY, J;WURZNER, R;MCCARTHY, CF (1994) 'HEREDITARY-DEFICIENCY OF THE 7TH COMPONENT OF COMPLEMENT AND RECURRENT MENINGOCOCCAL INFECTION - INVESTIGATIONS OF AN IRISH FAMILY USING A NOVEL HEMOLYTIC SCREENING ASSAY FOR COMPLEMENT ACTIVITY AND C7 M/N ALLOTYPING'. Epidemiology And Infection, 113 :275-281 [Details]
(1994) 'HEREDITARY-DEFICIENCY OF THE 7TH COMPONENT OF COMPLEMENT AND RECURRENT MENINGOCOCCAL INFECTION - INVESTIGATIONS OF AN IRISH FAMILY USING A NOVEL HEMOLYTIC SCREENING ASSAY FOR COMPLEMENT ACTIVITY AND C7 M/N ALLOTYPING'
EGAN, LJ,ORREN, A,DOHERTY, J,WURZNER, R,MCCARTHY, CF (1994) 'HEREDITARY-DEFICIENCY OF THE 7TH COMPONENT OF COMPLEMENT AND RECURRENT MENINGOCOCCAL INFECTION - INVESTIGATIONS OF AN IRISH FAMILY USING A NOVEL HEMOLYTIC SCREENING ASSAY FOR COMPLEMENT ACTIVITY AND C7 M/N ALLOTYPING'. Epidemiology And Infection, 113 :275-281 [Details]

Books

  Year Publication
(2008) Pharmacology and Therapeutics, Principals to Practice. Saunders, Philadelphia, 2008. Associate Editor.
Egan, L. (2008) Pharmacology and Therapeutics, Principals to Practice. Saunders, Philadelphia, 2008. Associate Editor. [Details]

Book Chapters

  Year Publication
'Ileoanal pouch: frequent evacuation'
Egan, L. J. & Phillips, S. F. 'Ileoanal pouch: frequent evacuation' In: Advanced Therapy in Gastroenterology and Liver Disease - 5. B.C. Decker, Hamilton. [Details]
'Mechanisms of action of drugs in IBD'
Egan, L. J. 'Mechanisms of action of drugs in IBD' In: Falk Symposium. [Details]
(2004) 'Tumor necrosis factor alpha'
Egan, L. J. (2004) 'Tumor necrosis factor alpha' In: Encyclopedia of Gastroenterology. In Johnson, L. R. Elsevier (USA). [Details]
(2003) 'Clinical pharmacology in inflammatory bowel disease: strategies to optimize current medical therapy'
Egan, L. J. & Sandborn, W. J. (2003) 'Clinical pharmacology in inflammatory bowel disease: strategies to optimize current medical therapy' In: Inflammatory Bowel Disease, From Bench to Bedside . Kluwer Academic Publishers. [Details]
(2001) 'Ileoanal pouch patient: evaluation of excessive bowel movements'
Egan, L. J. & Phillips, S. F. (2001) 'Ileoanal pouch patient: evaluation of excessive bowel movements' In: Advanced therapy of inflammatory bowel disease (2/e) IHamilton. [Details]
(1998) 'Drug therapy of Inflammatory Bowel Disease'
Egan, L. J. & Sandborn, W. J. (1998) 'Drug therapy of Inflammatory Bowel Disease' In: Drugs of Today. [Details]

Conference Publications

  Year Publication
(2006) INFLAMMATORY BOWEL DISEASE: GENETICS, BARRIER FUNCTION, IMMUNOLOGIC MECHANISMS, AND MICROBIAL PATHWAYS
Egan, LJ;Toruner, M (2006) NF-kappa B signaling - Pros and cons of altering NF-kappa B as a therapeutic approach INFLAMMATORY BOWEL DISEASE: GENETICS, BARRIER FUNCTION, IMMUNOLOGIC MECHANISMS, AND MICROBIAL PATHWAYS , pp.114-122 [DOI] [Details]
(2008) APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS
Plantivaux A, Szegezdi E, Samali A, Egan LJ. (2008) TRAIL resistance in colon cancer cells: is NF-kB involved APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS [Details]

Abstract

  Year Publication
(2010) Comparison of IBD and non-IBD associated colorectal cancer: a nationwide population-based study on presentation, treatment and survival in Ireland.
Ali, RAR,Dooley, C,Newell, J,Comber, H,Egan, LJ (2010) Comparison of IBD and non-IBD associated colorectal cancer: a nationwide population-based study on presentation, treatment and survival in Ireland. Abstract [Details]
(2010) Gastroenterology.
Raja Affendi Raja Ali, Zulquernain SA, Ryan AE, Colleran A, Hartnett L, O’Gorman A, Lee JM, Egan LJ (2010) Gastroenterology. Abstract [Details]
(2010) Analysis of 6 circulating cytokines and colonic STAT3 activation pattern in patients with inflammatory bowel disease of different disease activity and duration.
Ali, RAR,Hartnett, L,Egan, LJ (2010) Analysis of 6 circulating cytokines and colonic STAT3 activation pattern in patients with inflammatory bowel disease of different disease activity and duration. Abstract [Details]
(2010) Gastroenterology.
Ryan AE, Colleran A, O'Gorman A, Mureau C, Egan LJ (2010) Gastroenterology. Abstract [Details]
(2010) Gastroenterology Presentation.
Colleran A, Ryan AE, O’Gorman A, Liptrot CH, Dockery P, Egan LJ (2010) Gastroenterology Presentation. Abstract [Details]
(2009) Gastroenterology.
Ryan AE, Colleran A, O’Gorman A, Foran E, Egan LJ (2009) Gastroenterology. Abstract [Details]

Conference Poster

  Year Publication
(1994) Lymphoma in celiac disease Improved outcome with intensive combination chemotherapy. World Congresses of Gastroenterology.
Egan LJ, Walsh SV, Stevens FM, Connolly CE, Egan EL, McCarthy CF. (1994) Lymphoma in celiac disease Improved outcome with intensive combination chemotherapy. World Congresses of Gastroenterology. Conference Poster [Details]
(1994) Hereditary terminal complement deficiency and recurrent meningococcal infection.. National Scientific Medical Meeting. Irish Journal of Medical Science.
Egan LJ, Orren A, Doherty J, McCarthy CF. (1994) Hereditary terminal complement deficiency and recurrent meningococcal infection.. National Scientific Medical Meeting. Irish Journal of Medical Science. Conference Poster [Details]

Editorial

  Year Publication
(2014) A new hand on the titter: Taking over the editorship of the Journal of Crohn's and Colitis.
Egan, LJ (2014) A new hand on the titter: Taking over the editorship of the Journal of Crohn's and Colitis. Editorial [DOI] [Details]
(2014) Taking a closer look at IBD.
Egan, LJ,Sandborn, W (2014) Taking a closer look at IBD. Editorial [DOI] [Details]
(2007) Allopurinol and 6MP: Steering through the therapeutic obstacle course.
Egan, LJ (2007) Allopurinol and 6MP: Steering through the therapeutic obstacle course. HOBOKEN: Editorial [DOI] [Details]
(2007) A nudge in the right direction: Shaping the metabolic fate of thiopurines for therapeutic gain.
Egan, LJ (2007) A nudge in the right direction: Shaping the metabolic fate of thiopurines for therapeutic gain. NEW YORK: Editorial [DOI] [Details]
(2014) A new hand on the titter: Taking over the editorship of the Journal of Crohn's and Colitis.
Egan, LJ (2014) A new hand on the titter: Taking over the editorship of the Journal of Crohn's and Colitis. AMSTERDAM: Editorial [DOI] [Details]
(2017) Ten Years of the Journal of Crohn's and Colitis.
Egan, LJ (2017) Ten Years of the Journal of Crohn's and Colitis. Editorial [DOI] [Details]
(2007) A nudge in the right direction: Shaping the metabolic fate of thiopurines for therapeutic gain.
Egan, LJ (2007) A nudge in the right direction: Shaping the metabolic fate of thiopurines for therapeutic gain. Editorial [DOI] [Details]
(2007) Allopurinol and 6MP: Steering through the therapeutic obstacle course.
Egan, LJ (2007) Allopurinol and 6MP: Steering through the therapeutic obstacle course. Editorial [DOI] [Details]

Letter

  Year Publication
(1996) Celiac disease and T-cell lymphoma.
Egan, LJ,Stevens, FM,McCarthy, CF (1996) Celiac disease and T-cell lymphoma. Letter [Details]

Meeting

  Year Publication
(1995) ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA (EATL) IN THE WEST OF IRELAND - LOW-FREQUENCY OF EPSTEIN-BARR-VIRUS IN THESE TUMORS.
WALSH, SV,EGAN, LJ,MCCARTHY, CF,CONNOLLY, CE (1995) ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA (EATL) IN THE WEST OF IRELAND - LOW-FREQUENCY OF EPSTEIN-BARR-VIRUS IN THESE TUMORS. Meeting [Details]

Reviews

  Year Publication
(2016) Mesenchymal stromal cells (MSCs) and colorectal cancer - a troublesome twosome for the anti-tumour immune response?.
O'Malley, G;Heijltjes, M;Houston, AM;Rani, S;Ritter, T;Egan, LJ;Ryan, AE (2016) Mesenchymal stromal cells (MSCs) and colorectal cancer - a troublesome twosome for the anti-tumour immune response?. ORCHARD PARK: Reviews [DOI] [Details]
(2015) The intestinal epithelial cell cycle: uncovering its 'cryptic' nature.
McKernan, DP,Egan, LJ (2015) The intestinal epithelial cell cycle: uncovering its 'cryptic' nature. Reviews [DOI] [Details]
(2012) Inflammation, DNA methylation and colitis-associated cancer.
Hartnett, L,Egan, LJ (2012) Inflammation, DNA methylation and colitis-associated cancer. Reviews [DOI] [Details]
(2012) Inflammation, DNA methylation and colitis-associated cancer.
Hartnett, L;Egan, LJ (2012) Inflammation, DNA methylation and colitis-associated cancer. OXFORD: Reviews [DOI] [Details]
(2012) PHARMACOLOGICAL INHIBITION OF ENDOCANNABINOID DEGRADATION MODULATES THE EXPRESSION OF INFLAMMATORY MEDIATORS IN THE HYPOTHALAMUS FOLLOWING AN IMMUNOLOGICAL STRESSOR.
Kerr, DM,Burke, NN,Ford, GK,Connor, TJ,Harhen, B,Egan, LJ,Finn, DP,Roche, M (2012) PHARMACOLOGICAL INHIBITION OF ENDOCANNABINOID DEGRADATION MODULATES THE EXPRESSION OF INFLAMMATORY MEDIATORS IN THE HYPOTHALAMUS FOLLOWING AN IMMUNOLOGICAL STRESSOR. Reviews [DOI] [Details]
(2011) How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis.
Ali, RAR;Egan, LJ (2011) How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis. SHARJAH: Reviews [Details]
(2011) How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis.
Ali, RAR,Egan, LJ (2011) How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis. Reviews [Details]